The multicentre, randomised trial was conducted in China, but Sichuan-Kelun and Merck & Co will commercialise sac-TMT in other markets.

Pfizer is suing Novo Nordisk following the Danish pharma's last-minute bid to acquire Metsera, which Pfizer called “reckless” ...

D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market 4D-150.

IntoCell has announced a MoU with US-based contract development and manufacturing organisatioXcellon Biologics.

Bayer and BI have reported broadly similar efficacy outcomes for sevabertinib and Hernexeos in HER2-mutant NSCLC.

The Boston-based biotech is axing Phase II plans for its only clinical-stage asset, in a bid to maximise shareholder value.

Epioxa by Glaukos Corp received US Food and Drug Administration (FDA) approval on 20 October as the first and only ...

As healthcare systems work towards new sustainability goals, medical textiles have become a key focus for innovation.

Mounjaro generated sales of $6.5bn in Q3 2025, up 109% from the same period in 2024. Zepbound exhibited even higher growth – ...

Helex has raised $3.5m in a seed funding round spearheaded by pi Ventures to advance non-viral gene therapies for kidney ...

Health Canada has issued a Notice of Compliance (NOC) for AstraZeneca’s HER2-directed antibody drug conjugate (ADC) Enhertu.

The FDA's draft guidance is supposed to cut the cost and time-associated burden of biosimilar development, despite a mixed ...